After the first pandemic wave in Europe, seroprevalence surveys revealed that roughly one
in ten individuals had been infected with severe acute respiratory syndrome coronavirus 2 …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has surprised the world
with its range of disease manifestations, from asymptomatic infection to critical illness …

During the first year of the COVID-19 pandemic, more than 90 million cases were reported
globally, with nearl y 2 million deaths. Case reporting depends on several factors, including …

Little is known about the duration and protective capacity of the humoral immune response
to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In studies from Iceland1 …

As the initial phase of the COVID-19 pandemic passes its peak in many countries,
serological studies are becoming increasingly important in guiding public health responses …

Long Covid. 6, 7 Persisting absenteeism from work linked to COVID-19 and to other
circulating respiratory viruses since the lifting of public health measures has had negative …

Since December, 2019, coronavirus disease 2019 (COVID-19) has affected more than 100
000 patients globally. 1 COVID-19 is caused by the severe acute respiratory syndrome …

As of July 1, Belgium has 61 509 confirmed cases of severe acute respiratory syndrome
corona virus 2 (SARS-CoV-2) infection and 9754 related deaths. In early April, the ministry of …

The pandemic spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2),
the cause of COVID-19, has placed lives and economies of many countries under …

Several studies have shown that neutralising antibody level is a good biomarker for the
correlate of protection against SARS-CoV-2 infection. 1–3 However, results from these …